Trevogrumab

Trevogrumab (INN;^[1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.

Trevogrumab

Monoclonal antibody
Type	?
Source	Human
Target	growth differentiation factor 8
Clinical data
Other names	REGN1033
ATC code	none
Identifiers
CAS Number	1429201-24-0
ChemSpider	none
UNII	87T4327873
KEGG	D11242
Chemical and physical data
Formula	C6374H9884N1696O2018S46
Molar mass	144037.80 g·mol−1

This drug was developed by Regeneron Pharmaceuticals, Inc.^[2]